← All companies

GSK

GSK plc

GSK NYSE Pharmaceutical Preparations EDGAR ↗

$49.35

-0.35 -0.70%

Key statistics

from XBRL data in SEC filings

Market cap ⓘ

$213B

Revenue (TTM) ⓘ

—

Net income (TTM) ⓘ

—

EPS (TTM) ⓘ

—

P/E ratio ⓘ

—

Dividend yield ⓘ

—

Free cash flow ⓘ

—

Cash ⓘ

—

Total assets ⓘ

—

Gross margin ⓘ

—

52-week range ⓘ

$41.75 – $61.70

Recent SEC filings

40 most recent

Annual, quarterly & current reports

6-K DIRECTOR/PDMR SHAREHOLDING Sep 24, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Sep 22, 2026

6-K Sep 15, 2026

6-K GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA Sep 15, 2026

6-K RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA Sep 14, 2026

6-K JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC Sep 14, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Sep 11, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Sep 10, 2026

6-K JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE Sep 10, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Sep 9, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Sep 9, 2026

6-K Sep 8, 2026

6-K TOTAL VOTING RIGHTS Sep 1, 2026

6-K MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III Sep 1, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Aug 26, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Aug 24, 2026

6-K FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN Aug 24, 2026

6-K US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER Aug 24, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Aug 18, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Aug 13, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Aug 11, 2026

6-K TOTAL VOTING RIGHTS Aug 3, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Jul 30, 2026

6-K NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE Jul 28, 2026

6-K HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ Jul 28, 2026

6-K 2ND QUARTER RESULTS Jul 28, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Jul 24, 2026

6-K ADMISSION TO TRADING Jul 24, 2026

6-K JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS Jul 22, 2026

6-K BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE Jul 20, 2026

6-K AUDIT TENDER CONCLUSION Jul 17, 2026

6-K CAMLIPIXANT PHASE III RESULTS UPDATE Jul 17, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Jul 16, 2026

6-K GSK COMPLETES ACQUISITION OF NUVALENT, INC Jul 15, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Jul 14, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Jul 13, 2026

6-K POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER Jul 13, 2026

6-K HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ Jul 10, 2026

6-K DIRECTOR/PDMR SHAREHOLDING Jul 9, 2026

6-K DIRECTORATE CHANGE Jul 9, 2026